TABLE VII.

Aromatase inhibitor access and funding by drug and province, as at December 2006³⁴

	Anastrozole (Arimidex a)	Letrozole (Femara b)	Exemestane (Aromasin c)
Access	C, S	C, S	C, S
British Columbia	A	A	A
Alberta	A	A	A
Saskatchewan	N, R, L4	N, R, L4	N, R, L4
Manitoba	A	A	A
Ontario	L2, L4	L2, L4	L2, L4
Quebec	A	A	A
New Brunswick	C, L2, L4	C, L2, L4	C, L2, L4
Prince Edward Island	N, C	N, C	N, C
Nova Scotia	L2, L4	L2, L4	N
Newfoundland and Labrador	C, L1, L2	C, L1, L2	C, L1, L2

^aAstraZeneca Canada, Mississauga, ON.

^bNovartis Pharmaceuticals Canada, Dorval, QC.

^cPfizer Canada, Kirkland, QC.

C = compassionate release from pharmaceutical company; S = self-pay or third-party insurer, drug readily available through retail pharmacies; A = approved and fully funded provincially; N = not approved or funded in that province; R = recommended for funding, but not yet approved, still pending; L1 = limited access on a case-to-case basis (disease-specific factors); L2 = limited access based on coverage for specific patient groups only (patients over 65 years of age, or those receiving social assistance or welfare); L4 = limited access based on private payment of the drug (self-pay, third-party insurer, or manufacturer’s compassionate program), but drug administered by public cancer centre or hospital.